Hermetica Superfood Encyclopedia
The Short Answer
Phellinus igniarius produces polysaccharides (including 1,3-β-glucan), phenolics, flavonoids, and novel pyranoisochromenone derivatives (phelligridins) that modulate immune responses via SOD-like antioxidant activity, immunocyte activation, and direct cytotoxic mechanisms against transformed cell lines. In water extract studies (WEPI), the fungus demonstrated approximately 1.7-fold greater superoxide dismutase-mimicking activity than related species Phellinus linteus and reduced mutagen-induced revertants by 16.6–39.2% at 0.5–2 mg/plate in the Ames antimutagenicity assay.
CategoryMushroom
GroupMushroom/Fungi
Evidence LevelPreliminary
Primary KeywordPhellinus igniarius benefits
Willow Bracket Fungus — botanical close-up
Health Benefits
**Antioxidant Protection**: The water extract (WEPI) contains 12
0 ± 0.02 mg/g total phenolics and 12.0 ± 0.07 mg/g flavonoids, conferring approximately 1.7-fold greater superoxide dismutase-mimicking activity compared to P. linteus, effectively scavenging reactive oxygen species in cell-free and cell-based assays.
**Immunomodulation**
Polysaccharides and 1,3-β-glucan fractions activate innate immune pathways in murine models, stimulating macrophage and lymphocyte responses; immunostimulatory effects and tumor inhibition have been observed in animal studies, though specific mechanistic pathways in humans remain uncharacterized.
**Antimutagenic Activity**
WEPI reduced histidine revertant colonies in the Ames bacterial mutagenicity assay by 16.6–39.2% across doses of 0.5–2 mg/plate (e.g., 396 ± 7 revertants at 2 mg/plate versus controls), indicating potential interference with DNA-damaging agents.
**Anticancer Cytotoxicity**
Novel pyranoisochromenone derivatives—phelligridins H, I, and J—exhibit cytotoxicity against select cancer cell lines through unique carbon skeleton interactions, representing a structurally distinct class of fungal cytotoxic compounds with preliminary in vitro significance.
**Antiviral Neuraminidase Inhibition**
Sesquiterpenoid compounds isolated from P. igniarius inhibit H5N1 influenza neuraminidase activity in vitro, suggesting a potential mechanism for antiviral defense complementary to the immunomodulatory polysaccharide fraction.
**Glycemic Support via Exopolysaccharides**
Exopolysaccharides (EPS) produced by submerged fermentation stimulate insulin secretion in RINm5F pancreatic beta-cell lines, reaching a maximum of 0.615 µg/L at 2 mg/mL, alongside promoting beta-cell proliferation and reducing oxidative stress in vitro.
**Antiproliferative and Antioxidant Synergy**
Combined polysaccharide and phenolic content of WEPI (49.7 ± 0.4 mg/g and 12.0 mg/g, respectively) provides coordinated free-radical scavenging and immune activation that may collectively reduce oxidative DNA damage and support host tumor surveillance mechanisms in preclinical models.
Origin & History
Natural habitat
Phellinus igniarius is a bracket fungus (polypore) native to temperate forests across Europe, Asia, and North America, where it grows as a perennial woody conk on the trunks of deciduous trees, particularly willows, birches, and alders. It thrives in cool, moist forest environments and is a saprotrophic and weakly parasitic organism, causing white heart rot in host trees. Historically collected from wild stands rather than cultivated, it has gained interest in biotechnology for submerged fermentation to produce exopolysaccharides under controlled conditions.
“Phellinus igniarius has been recognized in European and Asian ethnomedicine for centuries, primarily used in folk traditions for its perceived tonic, anti-inflammatory, and immune-supportive properties, with records of use in Siberian, Chinese, and Northern European herbal traditions. In some Indigenous Siberian and Central Asian cultures, conk fungi of the Phellinus genus were prepared as teas or smoked preparations believed to ward off illness and support vitality, though P. igniarius was less prominently documented than its relative Inonotus obliquus (Chaga). The fungus shares ecological and cultural overlap with Chaga in northern birch and willow forest ecosystems, and its traditional use as a medicinal decoction likely preceded modern phytochemical characterization by many centuries. Academic interest in isolating phelligridins and polysaccharides from P. igniarius accelerated in the late 20th and early 21st centuries as screening programs for novel cytotoxic natural products expanded across Asian and European research institutions.”Traditional Medicine
Scientific Research
The existing evidence base for Phellinus igniarius consists entirely of in vitro cell assays, bacterial mutagenicity tests (Ames assay), and rodent model studies; no published human clinical trials have been identified in the available literature as of the most recent search. Key in vitro findings include antimutagenic reductions of 16.6–39.2% in the Ames test at 0.5–2 mg/plate, SOD-mimicking activity measurements in cell-free systems, insulin secretion stimulation of 0.615 µg/L maximum in RINm5F cells at 2 mg/mL EPS, and cytotoxicity data for phelligridin compounds against cancer lines, none of which include specified sample sizes or statistical power calculations typical of rigorous preclinical reporting. Animal immunostimulation and tumor inhibition studies are referenced in the literature but lack publicly reported effect sizes, sample sizes, or standardized outcome measures in accessible primary sources. Overall, the evidence is preliminary and mechanistically suggestive but insufficient to establish efficacy, optimal dosing, or safety parameters in humans, placing this ingredient firmly in early-stage preclinical research.
Preparation & Dosage
Traditional preparation
**Water Extract (WEPI)**
4 mg/g polysaccharides and 12
No established human dose; research preparations dissolve dried fungal material in hot water, yielding 49.7 ± 0..0 mg/g phenolics per gram dry weight; in vitro doses ranged 0.5–2 mg/plate or mg/mL.
**Polysaccharide Extract**
Isolated via precipitation from water extracts; standardized to polysaccharide content (up to 94.87% carbohydrates by GC/MS); no human dosing established.
**Fermentation-Derived Exopolysaccharides (EPS)**
128 g/L EPS and 6
Produced via submerged liquid fermentation with Tween 80 as surfactant, yielding maximum 0..76 g/L biomass; used at 0.5–2 mg/mL in cell studies.
**Traditional Preparation**
Historically prepared as decocted teas or water infusions from dried woody conk material in European and Asian folk medicine; fibrous structure limits direct consumption.
**Standardization**
No commercially standardized supplement product is established; research extracts are typically characterized by total polysaccharide, phenolic, and flavonoid content.
**Timing and Bioavailability**
No pharmacokinetic data available in humans; high molecular weight polysaccharides (1.715 × 10⁶ Da) likely require enzymatic or acidic degradation for intestinal absorption, which has not been quantified.
Nutritional Profile
Phellinus igniarius extracts are carbohydrate-dominant, with water extracts containing approximately 94.87% total carbohydrates by dry weight, of which polysaccharides account for 49.7 ± 0.4 mg/g. The phenolic content is 12.0 ± 0.02 mg/g and flavonoid content is 12.0 ± 0.07 mg/g, providing meaningful antioxidant phytochemical load. Polyhydric alcohols include mannitol at approximately 13% and ribitol at approximately 11% of extract composition, which may contribute osmotic and antioxidant effects. Mineral content includes copper (6.01 ± 0.22 mg/kg), iron (5.04 ± 0.88 mg/kg), and notably high chloride (greater than 3 g/kg), with trace arsenic at 1–2 mg/kg warranting monitoring in concentrated extracts. Macronutrient data such as protein and fat fractions have not been extensively reported for this species; bioavailability of high-molecular-weight polysaccharides (average 1.715 × 10⁶ Da) in the human gastrointestinal tract has not been quantified.
How It Works
Mechanism of Action
The polysaccharide fraction of Phellinus igniarius, particularly high-molecular-weight 1,3-β-glucan (EPS averaging 1.715 × 10⁶ Da), engages pattern recognition receptors such as Dectin-1 on macrophages and dendritic cells, triggering downstream NF-κB and MAPK signaling cascades that upregulate pro-inflammatory cytokines and enhance phagocytic activity during immune challenge. The phenolic and flavonoid constituents (each at approximately 12.0 mg/g in WEPI) directly scavenge superoxide and hydroxyl radicals and mimic superoxide dismutase enzymatic activity, reducing oxidative stress-mediated cellular damage at roughly 1.7-fold the potency observed in P. linteus extracts. Phelligridin derivatives (H, I, J) harbor novel pyrano[4,3-c]isochromen-4-one carbon skeletons that intercalate with or otherwise disrupt cancer cell proliferation pathways, producing cytotoxicity in transformed cell lines through mechanisms distinct from classical alkaloid or terpenoid anticancer agents. Sesquiterpenoids from the fungal biomass competitively inhibit H5N1 neuraminidase, blocking viral particle release from infected cells, while EPS-mediated beta-cell stimulation appears to involve direct membrane receptor interactions that potentiate glucose-dependent insulin secretory pathways in pancreatic cell models.
Clinical Evidence
There are no completed human clinical trials for Phellinus igniarius reported in the available scientific literature, representing a significant gap in translational evidence. Preclinical observations include antimutagenic activity in bacterial assays, immunostimulation and tumor suppression in murine models, neuraminidase inhibition in viral enzyme assays, and insulin-secretory effects in pancreatic cell lines—all of which constitute hypothesis-generating rather than confirmatory data. Effect magnitudes from in vitro studies (e.g., 16.6–39.2% mutagenicity reduction; ~1.7-fold SOD activity) are compelling enough to justify further investigation but cannot be extrapolated to human therapeutic outcomes without properly designed pharmacokinetic and clinical safety studies. Confidence in benefit claims for human use remains very low; all current applications are investigational.
Safety & Interactions
Formal human toxicology studies for Phellinus igniarius have not been published, and no maximum tolerated dose, no-observed-adverse-effect level (NOAEL), or clinical adverse event data are available. The presence of trace arsenic (1–2 mg/kg) in raw fungal material warrants caution with concentrated or prolonged extract use, particularly in populations with baseline heavy metal exposure or renal impairment, as cumulative arsenic burden could pose risk. The high chloride content (greater than 3 g/kg) in extracts may theoretically interact with electrolyte balance in individuals on diuretics, corticosteroids, or medications affecting renal chloride handling, though this is inferred from compositional data rather than observed clinical interactions. No specific drug interactions, pregnancy or lactation safety data, or pediatric use guidelines have been established; use during pregnancy or lactation is not recommended given the absence of safety evidence, and individuals with immunosuppressive conditions or on immunomodulatory therapy should consult a healthcare provider before use.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
Phellinus igniarius (L.) Quél.Willow Bracket FungusWillow ConkFalse Tinder FungusFomes igniariusBoletus igniarius
Frequently Asked Questions
What is Phellinus igniarius used for medicinally?
Phellinus igniarius is investigated primarily for antioxidant, immunomodulatory, anticancer, and antiviral properties based on preclinical research. Its water extract (WEPI) contains polysaccharides (49.7 mg/g), phenolics (12.0 mg/g), and novel phelligridin compounds that show cytotoxicity against cancer cells and SOD-mimicking antioxidant activity approximately 1.7-fold stronger than related species. No human clinical applications have been validated as of current evidence.
Does Phellinus igniarius have clinical trial evidence in humans?
No human clinical trials for Phellinus igniarius have been published in the available scientific literature. All current evidence derives from in vitro cell assays, bacterial mutagenicity tests (Ames assay), and animal model studies, none of which included reported sample sizes meeting standard clinical trial criteria. This limits any conclusions about efficacy or safety in human populations.
What are the key bioactive compounds in Phellinus igniarius?
The principal bioactives are high-molecular-weight polysaccharides (average 1.715 × 10⁶ Da including 1,3-β-glucan), phenolics and flavonoids (each approximately 12.0 mg/g in water extracts), pyranoisochromenone derivatives called phelligridins H, I, and J, sesquiterpenoids with neuraminidase-inhibiting activity, and polyhydric alcohols mannitol (approximately 13%) and ribitol (approximately 11%). These fractions collectively account for the fungus's antioxidant, cytotoxic, and immunostimulatory properties observed in laboratory studies.
Is Phellinus igniarius safe to consume?
Formal human safety and toxicology data for Phellinus igniarius are absent from published literature. The fungus contains trace arsenic (1–2 mg/kg) and high chloride (greater than 3 g/kg) in extracts, which may be concerns at high supplemental doses or with prolonged use, particularly for individuals with kidney disease or electrolyte disorders. Its extremely fibrous woody structure also prevents direct consumption, and concentrated extracts should be used with caution pending formal toxicological assessment.
How does Phellinus igniarius compare to Chaga (Inonotus obliquus)?
Both Phellinus igniarius and Inonotus obliquus (Chaga) are bracket fungi from similar boreal forest ecosystems with overlapping bioactive profiles including polysaccharides, phenolics, and immunomodulatory compounds. However, Chaga has a significantly larger body of published research, broader traditional use documentation, and more extensive phytochemical characterization including betulinic acid and inotodiol. Phellinus igniarius is distinguished by its unique phelligridin compounds and sesquiterpenoid neuraminidase inhibitors, but its overall evidence base is substantially thinner than Chaga's preclinical literature.
What is the difference between Phellinus igniarius extract forms (water vs. alcohol)?
Water extracts (WEPI) of Phellinus igniarius concentrate polysaccharides and flavonoids, delivering 12.0 mg/g total phenolics and demonstrating superior antioxidant activity comparable to superoxide dismutase enzymes. Alcohol extracts may capture different bioactive compounds including triterpenes, but water extraction is the most studied form for immune activation and antioxidant benefits in research.
Is Phellinus igniarius suitable for people with autoimmune conditions?
While Phellinus igniarius polysaccharides activate innate immune pathways, individuals with autoimmune diseases should consult a healthcare provider before supplementing, as immune-stimulating compounds may theoretically exacerbate autoimmune responses. The ingredient's immunomodulatory effects are primarily documented in cell and animal studies rather than autoimmune patient populations.
How does the antioxidant potency of Phellinus igniarius compare to other medicinal mushrooms by measurable standards?
Phellinus igniarius water extract demonstrates approximately 1.7-fold greater superoxide dismutase-mimicking activity compared to P. linteus in cell-free assays, making it notably more potent on this specific antioxidant marker. This superior ROS-scavenging capacity in both cell-free and cell-based models positions it among the more antioxidant-rich medicinal mushroom species studied.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w phellinus-igniarius-phellinus-igniarius curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
